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Abstract
Background: Non alcoholic fatty liver disease (NAFLD) results from alteration in lipid synthesis and elimination
mechanisms such as very-low density lipoprotein (VLDL) production and de novo lipogenesis. Persistent organic
pollutants (POPs) are chemicals that were mostly used historically as pesticides, solvents, flame retardant, and other
applications. Among POPs, polychlorinated biphenyls (PCB) have been recognized to be of environmental and
potential toxicologic concerns. Specifically, PCB126 could act as endocrine disruptors and has recently been
associated with hepatic fat accumulation. The purpose of the study was to investigate the effects of PCB126
on the molecular development of NAFLD using hepatocyte and rat models.
Methods: Hepatocytes were exposed to PCB 126 for 72 h and lipid accumulation in cells was quantified by
Oil-Red-O. Rats were injected with a single dose of PCB126 or vehicle. Seven days later, liver triglycerides
(TAG) content was measured along with protein quantification of hepatic microsomal triglyceride transfer
protein (MTP), sterol regulatory element-binding protein 1c (SREBP1c) and diacylglycerol O-acyltransferase 2
(DGAT-2).
Results: Exposure to PCB126 resulted in significant increases of lipid accumulation in hepatocytes (38 %, P <0.05)
and hepatic TAG concentrations (64 %, P <0.001) in rats compared to respective control groups. Rats with fatty
livers depicted lower MTP (40 %, P <0.02), higher SREBP1c (27 %, P < 0.05) and DGAT-2 (120 %, P < 0.02) protein
content levels compared to Placebo group in rats.
Conclusions: It seems that exposure to PCB126 has an important emerging role in the pathophysiology of NAFLD
by 1) altering elimination mechanisms such as VLDL synthesis and secretion, through MTP; and 2) increasing
hepatic TAG synthesis mechanisms through DGAT 2 and SREBP1c.
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Background
Liver plays an essential role in the biogenesis of major
metabolites such as lipids. However, an important in-
creased in hepatic fat depot leads to the development of
NAFLD. NAFLD is the most prevalent liver disease in
North America and reaching approximately 20 % of the
population worldwide, and affecting both adults and
children [1, 2]. NAFLD has become a common cause
of chronic metabolic diseases such as steatohepatitis,
diabetes [3] and metabolic syndrome [4]. Historically
NAFLD was linked to overnutrition, physical inactivity
and pharmacology. However, emerging studies have
demonstrated that additional contributing factors may
play a role in the development of NAFLD, such as
persistent organic pollutants (POPs).
Persistent organic pollutants are chemicals that were
mostly used historically as pesticides, solvents, and
flame-retardants and have been released in the environ-
ment. In North America, POPs have been recognized to
be of environmental and potential toxicologic concern,
as a result, a variety of POPs have been banned from use
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since the late 1970’s [5]. However, due to their persist-
ence and lipophilicity, these compounds will remain
present in the environment for decades and accumulate
in living organisms [6]. POPs also accumulate in adipose
tissue and are continuously released from adipose tissue
to the circulation and to vital organs with lipid content
[7]. In humans, a National Health and Nutrition
Examination Survey (NHANES) study showed that the
total participants had detectable circulating POPs levels
[8]. POPs regroup polychlorinated biphenyls (PCBs), a
family of 209 different congeners. A total of 1.3 million
tons of PCBs were manufactured prior 1977 for use in
electrical and other industrial applications [9]. PCB126
is the most potent and ubiquitous in the environment
amongst congeners [10]. Recent studies have reported
that the presence of PCB126 could act as endocrine dis-
ruptors at the liver level and lead to fatty liver [11].
Hepatic lipid accumulation results from altered intra-
hepatic TAG elimination and synthesis mechanisms.
Specific key-molecules such as MTP is involved in lipid
elimination pathways through VLDL production and
secretion, while synthesis pathways regroup DGAT-2
and SREBP1c.
Hepatic VLDL production is a complex process involv-
ing several enzymes to carry TAG from liver to periph-
eral tissues [12]. MTP plays a pivotal role in the
assembly and secretion of apoB-containing lipoproteins
[13]. MTP is a heterodimeric protein expressed on the
luminal side of ER composed of a catalytic subunit of
97 kDa and a multifunctional protein of 55 kDa, disul-
fide isomerase [14]. Molecular processes such as fatty
acid synthesis and esterification also regulate hepato-
cytes TAG content. In the liver, DGAT has a role in
synthesizing TAG from either fatty acids synthesized de
novo or from fatty acids taken up from the circulation.
Two DGAT enzymes were identified, DGAT1 and
DGAT2. While DGAT1 seems to be associated to TAG
synthesis and VLDL secretion stimulation [15], DGAT2
appears to catalyze the final step in the pathway leading
to de novo synthesis and intracellular accumulation of
TAG [16]. SREBPs are major transcription factors that
regulate the expression of genes involved in lipid synthe-
sis in the liver. Three isoforms exist, SREBP-1a, −1c
and −2 [17, 18]. SREBP-2 activates genes involved in
cholesterol metabolism, whereas SREBP-1 regulates
genes involved in the metabolism of fatty acids [240].
SREBP-1c is the predominant isoform expressed in liver
[18] and is mostly responsible for the expression of genes
involved in hepatic fatty acid biosynthesis [19].
Over the last decade, interactions of PCB126 with ner-
vous [20] and reproductive [21] metabolic activities for
instance, have attracted much interest. However, the
effects of PCB126 on the liver, specifically on the under-
lying molecular mechanisms leading to NAFLD have not
yet been defined. Therefore the purpose of this research
study is to understand the molecular effects of PCB126
exposure on VLDL production, estimated through MTP,
and on hepatic lipid synthesis, via DGAT2 and SREBP1c
using human cell culture and animal model.
Methods
Cell culture
PCB126 was obtained from Ultra Scientific (North
Kingstown, RI, USA) and dimethyl sulfoxide (DMSO)
was obtained from Sigma-Aldrich (St. Louis, MO, USA).
PCB126 was dissolved in DMSO as stock solution and
diluted with Differentiation Medium (Zenbio Inc, North
Carolina, USA, cat# DM-2) to specific concentration
before being added to the cells in culture. The final con-
centration of DMSO was never greater than 0.3 % (v/v).
Human hepatocytes (ZenBio Inc., Durham, NC) were
initially plated at a density of 9.4 104 cells/well. Follow-
ing a 6 to 8 h incubation period for cell attachment,
hepatocytes were exposed to PCB126 [2.5uM] for 72 h
[22]. Control group was treated in DMSO (0.3 %) and
chloroquine [25uM] served as a positive control. Cells
were incubated at 37 °C in a humidified 95 % air-5 %
CO2 atmosphere incubator in 48 well plates.
Lipid quantification was assessed in human hepatocytes
using steatosis colorimetric assay (Cayman Chemical
Company, Ann Arbor, Michigan).
Animal care
Female Sprague–Dawley strain rats (Charles River, St-
Constant, Quebec, Canada), weighing 200-250 g upon
their arrival were housed in pair and had ad libitum
access to food and tap water. Their environment was
controlled in terms of light (12:12-h light–dark cycle
starting at 6:00 AM), humidity and room temperature
(20-23 °C). All rats were fed a standard diet (Harlan
2018 Rodent Diet, Harlan Teklad Laboratory) and had
access to water ad libitum. The sham group received a
single ip injection of corn oil (0.14 ml/kg) while experi-
ment group received PCB126 (1.05 umol/kg) dissolved
in corn oil [23]. All procedures were approved by the
Animal Care Committee of the University of Ottawa and
adhered to the guidelines established by the Canadian
Council on Animal Care.
Tissue sampling
Following 7 days after the injection, and after complete
anaesthesia (sodium pentobarbital, 65 mg/kg, ip.), the
abdominal cavity was rapidly opened following the me-
dian line of the abdomen. Blood was rapidly (<45 s)
drawn from the abdominal vena cava (~4 ml) and trans-
ferred in tubes pretreated with EDTA (15 %). Blood was
centrifuged (3 000 g for 10 min, 4 °C) and the plasma
were stored at − 80 °C until analyses. The liver was
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excised, the median lobe immediately frozen used for tri-
acylglycerol determination and protein quantification.
Western immunoblotting
Briefly, 200 mg of liver was homogenized in Lysis Buffer
(extraction buffer) with Na3VO4 1 mM and protease in-
hibitor cocktail using a polytron, sonicated and centri-
fuged at 13,000 g, 4 °C for 20 min. The infranatant was
collected with a blunt-tipped Pasteur pipette and stored
at -80 °C until protein determination. All samples
(50 μg of proteins) were separated on a 10 % SDS-
polyacrylamide gel and electrotransferred onto nitro-
cellulose membranes. Membranes were blocked 1-h in
Phosphate-buffered saline containing 0.05 % Tween
20 (PBST 0.05 %) and 5 % non-fat dry milk at 4 °C.
The blot was then incubated with primary antibody
overnight. After five washes in PBST (0.05 %), the
membrane was incubated for 45 min with secondary
antibody (Novus Biologicals, Littleton, CO) at room
temperature. Then the membrane was washed five
times for 15 min each time in PBST (0.05 %) before
revealing with West Pico (Fisher Scientific Company).
The resulting signal was acquired with ChemiDoc-It
Imaging System (Fisher Scientific Company) and the
bands were quantified with the use VisionWorks®LS
(UVP, LLC, Upland, CA) software and expressed as
arbitrary units. Equal protein loading was determined
using ß-actin (Sigma, Saint Louis, Missouri, USA).
Analytical procedures
Plasma TAG levels were determined with an enzymatic
colorimetric assay available from SIGMA (Saint Louis,
Missouri, USA). Liver TAG concentrations were esti-
mated from glycerol released after ethanolic KOH hy-
drolysis by using commercial kits from SIGMA (Saint
Louis, Missouri, USA).
Statistical analysis
Values are expressed as mean ± S.E. Statistical analyses
were performed using a one-way analysis of variance
(ANOVA) for non-repeated measures. Fisher’s LSD post
hoc test was used in the event of a significant (p < 0.05)
F ratio. Significance was accepted at p < 0.05. All ana-




As illustrated in Fig. 1a hepatocytes lipid accumulation
seen by microscope by Oil-Red-O and (B) measured by
colorimetry (OD 490 nm) after Oil-Red-O extraction
from lipid droplets, was 38 % greater in cells treated
with PCB126 [2.5uM] for 72 h (0.23 ± 0.01 OD490nm)
compared to Control (DMSO) (0.17 ± 0.007 OD490nm)
group (P < 0.001). Although PCB126 treated cells
depicted 14 % higher lipid content than Chloroquine, a
potential lipid droplet infiltration inducer (0.20 ± 0.01
OD490nm), statistical significance was not reached (P < 0.08).
The cells treated with Chloroquine depicted 21 % higher
lipid content than the Control group (P < 0.04).
Rats
PCB126 injections in rats resulted in higher hepatic
TAG content (64 %) compared to Control group injected
with Corn oil (21.3 ± 1.3 vs 35.2 ± 3.1 mg/g; P < 0.001)
(Fig. 2). Rats treated with PCB126 had 80 % more
plasma TAG compared to Corn Oil group (0.35 ± 0.06 vs
0.64 ± 0.08 mM, P < 0.02) (Fig. 3). All hepatic protein
contents are expressed in arbitrary units (AU). Immuno-
blotting of MTP resulted in a 40 % decrease in PCB126-
injected rats compared to Corn Oil group (1.4 ± 0.1 vs
0.8 ± 0.1 AU; P < 0.02) (Fig. 4). In contrast, protein con-
tent of DGAT-2 revealed to be 120 % higher (1.29 ± 0.2
Fig. 1 Lipid accumulation in hepatocytes. (a) Neutral lipid staining in hepatocytes using Oil-Red-O exposed to DMSO (Control), Chloroquine and
PCB126 [2.5 μM] viewed by light microscopy (magnification 40x). (b) Lipid quantification by colorimetry after dye extraction from lipid droplet
(OD 490 nm). *Significantly different from Control rats p < 0.05. n = 8-11. Control = White; Chloroquine = Grey; PCB126 = Black
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vs 2.85 ± 0.6 AU; P < 0.02) (Fig. 5) and SREBP1c was
26.5 % greater (0.87 ± 0.07 vs 1.09 ± 0.07 AU; P < 0.05)
(Fig. 6) compared to control rats.
Discussion
In the present study, we observed that seven days of ex-
posure to PCB126 lead to significant increases of lipid
content in hepatocytes and in liver of rats. Our results
strongly suggest that the presence of PCB126 is related
to important hepatic fat accumulation. Accordingly,
Wahlang et al. (2013) revealed that PCB 153 exposure in
high fat-fed mice was associated with an increased hep-
atic TAG content in C57Bl/6 J mice compared to vehicle
control group [24]. While, PCB-77 induced obesity in
C57B/6 mice and promoted differentiation of 3T3L1 adi-
pocytes [25]. Together, these results imply an important
association between PCBs exposure and increased fat
accretion.
There are likely multiple factors involved in hepatic fat
accumulation. We report an important decrease in MTP
protein content in PCB126 treated rats compared to
Corn oil injected group (Fig. 4). Deficiency of MTP gene
in mice [26, 27] and gene polymorphism in humans [28]
have been associated with the development of NAFLD.
Also, pharmacological inhibition of MTP in rats and
humans increased liver TAG content ranging from 30–
1000 % compared to control counterparts [29, 30].
Together, these results suggest that variations of the
Fig. 2 Hepatic TAG content (mg/g). *Significantly different from Control p < 0.001. n = 9-11. Control = White; PCB126 = Black
Fig. 3 Plasma Triglycerides concentrations (nM). n = 7. *Significantly different from Control group p < 0.02. Control =White; PCB126 = Black
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expression and activity of MTP significantly affect hep-
atic lipid. However, to our knowledge there are no pub-
lished studies on the effects of PCBs on hepatic MTP
content and liver TAG accumulation. Therefore in our
study, we can conclude that an altered expression of
MTP resulting from PCB126 exposure might potentially
cause important TAG accumulation in hepatocytes.
MTP plays a crucial role in the synthesis and hepatic
VLDL secretion, thus on plasma TAG levels. Pharmaco-
logical inhibition of MTP has been mainly used in the
treatment of hypertriglyceridemia in humans (Cuchel
2013; Raval 2012). Administration of a MTP inhibitor
for two weeks resulted in a 600 % increase in concentra-
tions of TAG liver and a decrease of 100 % of plasma
TAG in comparison to control rats [31]. In mice, de-
letion or deficiency of hepatic MTP gene results in
alteration of the VLDL secretion, reflected by signifi-
cantly lower plasma concentrations of plasma triglyc-
erides levels compared to control mice [26, 27, 32].
Conversely, an increased MTP protein content (161 %) in
the liver results in lipoprotein overproduction (30 %) in a
fructose-fed hamster model of insulin resistance [33–35].
Although, our results reveal that despite the fact that
MTP content was lower by 40 %, PCB126 injected rats in
Fig. 4 MTP. Western blotting of MTP measured by optical density (OD). n = 8. *Significantly different from Control rats p < 0.02.
Control = White; PCB126 = Black
Fig. 5 DGAT2. DGAT2 was quantified by optical density (OD) using Western Blot. n = 5-7. *Significantly different from Control group
p < 0.02. Control = White; PCB126 = Black
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our study showed nearly 80 % higher plasma TAG con-
centrations than in control group (Fig. 3). These results
are in line with several studies that have reported positive
associations between PCBs and serum lipid in humans
[36] and animals [37–39]. Mice had significant increase
(269 %) in plasma TAG concentrations following oral ad-
ministration of Aroclor 1254 for 14 days when compared
with the control group [39]. As well, continuous orally
daily exposure of various concentrations of Aroclor 1254
monkeys for 152 weeks in female rhesus was associated
with increased in plasma TAG ranging from 30–56 % [37].
Whereas MTP content was lower in our PCB126 exposed
rats, we hypothesize that increases in plasma TAG levels
may occur due to increased hepatic synthesis of TAG and
production of larger VLDL particles. Production of VLDL
with a larger size implies that fewer particles are being
secreted to account for the similar TG production
rates. In support of our hypothesis, one study reported
a 30 % increase in size of VLDL particles measured
directly in the ER in male rats injected with PCBs
[40]. Furthermore, in normal and T2D subjects, an
overproduction of large VLDL particles is the major
determinant of plasma TG levels and is mainly caused
by liver fat content [41, 42].
Hepatic TAG content is partly regulated by fatty acid
synthesis and esterification processes. DGAT2 catalyzes
the final step in the G3P pathway leading to TAG syn-
thesis. Our results revealed a substantial increase of
120 % in hepatic DGAT2 protein content in our PCB126
treated rats compared to Corn oil group (Fig. 5). In line
with our results, a recent study reported that DGAT-2
gene was differentially expressed (4.8-fold) in mouse
lungs after 3-weeks of polluted ambient air exposure
relative to control mouse [43]. Mice overexpressing
hepatic DGAT2 showed a 260 % increase in liver TAG
concentrations [44]. While suppression of DGAT2 with
antisense oligonucleotide treatment improves hepatic
steatosis in a diet induced NAFLD [45] and obesity [46,
47] rat models. On the whole, these results suggest an
important contributing role of DGAT2 in lipid accumu-
lation and possibly leading to the development of
NAFLD in our rats contaminated with PCB126.
Moreover, a recent study has reported that DGAT2 is
specialized for glycerol 3-phosphate (G3P) incorporation
into TAG, however it seems that the origin of these G3P
are not from exogenous preformed fatty acid [48]. A
possibility emerged that DGAT2 may be specialized for
the utilization of de novo synthesized fatty acids [49].
Endogenously fatty acid synthesis occurs predominantly
through de novo lipogenesis (DNL), both liver and
adipose tissue. SREBP1c has been closely related to
development of hepatic steatosis [50, 51] and hypertri-
glyceridemia [50]. Our results shows that our steatotic
rats exposed to PCB126 depicted significantly higher
SREBP1c protein concentration in their livers (Fig. 6).
Similarly, a significant increase in the expression level of
SREBP1c was induced in rats fed farm salmon contain-
ing various POPs [52].
Conclusions
Environmental pollutants have emerged as new contrib-
uting actors for their suspected endocrine and metabolic
disruption activity leading to the development of
NAFLD. The results emerging from this study bring
valuable molecular information on how lipotoxic com-
pounds such as PCB126 interfere with the normal
Fig. 6 SREBP1c. SREBP1C protein content measured by Western Blot and reported by optical density (OD). n = 8. *Significantly different from
Control rats p < 0.05. Control = White; PCB126 = Black
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functioning of vital metabolic pathways in the liver and
are clearly associated with the molecular development of
NAFLD.
A potential weakness of this study includes the i.p.
route of administration of PCB126 and that a single dose
of PCB 126 was used. PCBs are known to concentrate
within adipose tissue and liver. Although PCB 126 levels
were not measured in our livers, we expect them to be
in line with to those in the National Toxicology Program
Report [53]. Further in vivo studies are needed to more
fully understand the mechanisms involved in PCB126
induced NAFLD. It already been reported that alter-
ation in oxidative pathways may lead to ectopic fat ac-
cumulation in various organs including liver [54, 55].
Also, simultaneous co-exposures to chemicals and
whether they may act in an additive, synergistic, or an-
tagonistic manner must be taking in account in future
study designs.
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